Connect with us

Covid-19

WHO dashes hope of COVID-19 victims with new revelation

Published

on

COVID-19: NCDC confirms 135 new infections, total now 161,409
Spread The News

The anticipation that the first use of COVID-19 vaccine may start this year have been dashed as the World Health Organization [WHO] has revealed that the first use of the vaccine cannot be expected until early 2021.

Head of WHO emergencies programme, Mike Ryan, who disclosed this said the UN health agency is working to ensure fair vaccine distribution, but in the meantime, it is key to suppress the virus’ spread.

Ryan said, ‘’We’re making good progress, noting that several vaccines were now in phase 3 trials and none had failed, so far, in terms of safety or ability to generate an immune response. Realistically it is going to be the first part of next year before we start seeing people getting vaccinated.”

He said that WHO has been working to expand access to potential vaccines and to help scale up production capacity.

Going further, Ryan said, “And we need to be fair about this, because this is a global good. Vaccines for this pandemic are not for the wealthy, they are not for the poor, it’s for everybody.”

Pfizer and German biotech BioNTech have both revealed that the United States Government is expected to pay $1.95 billion to buy 100 million doses of a COVID-19 vaccine being developed by the 2 drug firms if it turns out safe and effective.

The WHO chief also cautioned schools to be careful about re-opening until community transmission of COVID-19 is under control.

Ryan said, “We have to do everything possible to bring our children back to school, and the most effective thing we can do is to stop the disease in our community. Because if you control the disease in the community, you can open the schools.”

Recall that a vaccine trial for the COVID-19 disease by a joint team of University of Oxford researchers and pharmaceutical firm, AstraZeneca Plc showed strong immune response in early testing with humans.

Also, the Modena vaccine candidate in its trial produced a robust immune response in all the 45 patients in its first phase of the human trial.

 

Trending